• Gamma-linolenic Acid: Next-Generation Strategies for Transla

  2026-07-07

  This thought-leadership article explores the evolving role of gamma-linolenic acid (GLA) in translational inflammation research, examining its mechanistic functions, experimental validation, and its emerging strategic relevance in disease modeling and therapeutic development. By synthesizing insights from recent immunometabolic studies and highlighting APExBIO’s GLA product, the article provides actionable guidance for researchers aiming to bridge preclinical findings with clinical innovation.

• Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Linker Applicat

  2026-07-07

  Mc-Val-Cit-PABC-PNP offers a cathepsin B-cleavable ADC peptide linker designed for targeted drug delivery research, enabling selective payload release in lysosomes. It is not suitable for aqueous, diagnostic, or therapeutic applications, and is optimized for organic solvent-based antibody-drug conjugate synthesis workflows.

• MALAT1/miR-135b-5p/GPNMB Axis Controls Proliferation in PD M

  2026-07-06

  The reference study by Lv et al. uncovers a regulatory axis involving the long non-coding RNA MALAT1, miR-135b-5p, and GPNMB in Parkinson’s disease (PD) cell models. Their findings clarify how MALAT1 promotes cell apoptosis and inhibits proliferation through miR-135b-5p sequestration and GPNMB modulation, suggesting novel molecular targets for PD research.

• Universal nPEC Method for Dual-Loaded Liposome Efficiency

  2026-07-06

  This study establishes nanoparticle exclusion chromatography (nPEC) as a robust, universally applicable technique for accurately determining the encapsulation efficiency of both hydrophilic and lipophilic drugs in dual-loaded liposomes. The findings address a major analytical bottleneck in combinatorial drug delivery, offering new precision for researchers examining complex nanocarrier systems.

• Pravastatin Sodium: Applied Protocols for HMG-CoA Reductase

  2026-07-05

  Pravastatin sodium empowers researchers to achieve precise, reproducible cholesterol biosynthesis inhibition across cellular and animal models. This guide delivers hands-on workflows, troubleshooting strategies, and insights from the latest transporter and hepatocyte studies—bridging rigorous bench science with translational impact.

• Targeting GOT1 in PDAC: Ziprasidone-Induced Redox Imbalance

  2026-07-04

  This article examines a recent study demonstrating how ziprasidone, a GOT1 inhibitor, disrupts glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC) cells. The findings highlight the mechanistic link between GOT1 inhibition, altered antioxidant balance, and reduced tumor proliferation, offering a promising direction for metabolic cancer therapy.

• Network Pharmacology Uncovers SFI’s Anti-Glioma Mechanism vi

  2026-07-03

  A recent study elucidates how Shenqi Fuzheng injection (SFI) inhibits glioma cell proliferation and migration by targeting the SRC/PI3K/AKT pathway, integrating network pharmacology and experimental validation. These findings clarify SFI’s mechanism and inform future anti-angiogenic research focused on malignant gliomas.

• Cycloheximide: Protein Biosynthesis Inhibitor for Precision

  2026-07-03

  Cycloheximide delivers unmatched control over protein synthesis, enabling researchers to dissect translation-dependent cellular mechanisms with temporal precision. This guide details best-practice workflows, troubleshooting strategies, and real-world applications, showing how APExBIO's Cycloheximide accelerates apoptosis and protein turnover research.

• Angiotensin 1/2 (2-7): Applied Workflows in Blood Pressure R

  2026-07-02

  Angiotensin 1/2 (2-7) peptide offers unparalleled precision for dissecting the renin-angiotensin system in cardiovascular and infectious disease models. Streamlined workflows, high solubility, and robust purity from APExBIO make it the peptide of choice for advanced blood pressure regulation and receptor-binding studies.

• Cyclopamine: Unlocking Translational Pathways in Cancer and

  2026-07-02

  Explore the mechanistic depth and translational impact of Cyclopamine, a Hedgehog signaling inhibitor, with insights into protocol design, competitive landscape, and cross-disciplinary applications—grounded in recent advances and original research.

• MLN4924 HCl Salt: Precision NEDD8-Activating Enzyme Inhibiti

  2026-07-01

  MLN4924 HCl salt provides researchers with a highly selective, DMSO-soluble tool for dissecting the neddylation pathway in cancer and virology research. Its unique mode of action enables advanced experimental workflows, precise modulation of cullin-RING ligase activity, and robust analysis of protein degradation mechanisms.

• Toremifene Citrate: Molecular Mechanisms and Translational I

  2026-07-01

  Explore the molecular pharmacology of Toremifene Citrate as an oral selective estrogen receptor modulator, with a focus on translational assay design and practical implications for hormone receptor research. This article delivers a deeper mechanistic and protocol-driven perspective not found in standard application guides.

• LNP-mRNA-Engineered Fibroblasts Mitigate Disc Degeneration

  2026-06-30

  This study introduces a dual-therapeutic approach using fibroblasts engineered with lipid nanoparticle (LNP)-delivered mRNA encoding TNF-α antibodies to counteract intervertebral disc degeneration (IVDD) by modulating the inflammatory microenvironment. The findings demonstrate improved disc regeneration and attenuation of inflammation compared to conventional fibroblast therapies, highlighting translational potential for degenerative spine disorders.

• TaqI Restriction Endonuclease: Protocols and Troubleshooting

  2026-06-30

  TaqI Restriction Endonuclease (SKU K3053) offers rapid, sequence-specific DNA digestion for molecular biology workflows involving plasmid, PCR, or genomic DNA. It is optimized for research use, providing fast, sticky-end cleavage and colored buffer tracers for streamlined electrophoresis, but is not suited for diagnostic or clinical applications.

• Enhanced Lysosomal Exocytosis in MPS IVA Cartilage Pathology

  2026-06-29

  This study reveals that increased lysosomal exocytosis and altered growth factor signaling are key contributors to cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA (MPS IVA). The work shifts focus beyond substrate accumulation, highlighting how lysosome-mediated protease dynamics disrupt skeletal development and providing a new framework for understanding lysosomal storage disorders.

374 records 7/25 page Previous Next First page 上5页 678910 下5页 Last page